GlassScriptPhysician profile
Karin D Machnau
NPI 1508852302
$5,535.67
in general payments reported to CMS, 2019-2025
35 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $354 · 2021: $607 · 2022: $509 · 2023: $1,572 · 2024: $1,025 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.48 |
| Education | $130.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.69 | 2020-2025 | |
| Amgen INC. | $648.72 | 2019-2025 | Otezla, Enbrel, Otezla |
| Janssen Biotech, INC. | $532.43 | 2021-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $298.24 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $292.67 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $267.49 | 2019-2025 | Odomzo, Blu-U, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $255.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $239.45 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $215.39 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $212.92 | 2021-2023 | Xeomin |
| Dermavant Sciences, INC. | $209.25 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.20 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $167.17 | 2020-2021 | |
| Pfizer INC. | $156.36 | 2019-2025 | |
| Ucb, INC. | $148.17 | 2021-2025 | Bimzelx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $140.18 | 2019 | |
| Genzyme Corporation | $87.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.17 | 2023 | Spevigo |
| Leo Pharma INC. | $53.42 | 2019-2025 | Adbry |
| Organon LLC | $52.63 | 2025 | Vtama |
| Allergan, INC. | $47.71 | 2019 | |
| Mayne Pharma Commercial LLC | $40.72 | 2025 | |
| Botanix Sb INC | $38.65 | 2025 | Sofdra |
| Almirall LLC | $38.34 | 2021-2023 | Klisyri |
| Prugen, INC. Pharmaceuticals | $35.64 | 2019 | |
| Arcutis Biotherapeutics, INC. | $34.37 | 2023-2024 | Zoryve |
| Revance Therapeutics, INC. | $32.16 | 2024 | Daxxify |
| Fidia Pharma USA INC. | $24.09 | 2025 | |
| Journey Medical Corporation | $22.03 | 2025 | |
| Smith+Nephew, INC. | $17.72 | 2023 | Pico 7 |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Incyte Corporation | $15.66 | 2023 | Opzelura |
| Merck Sharp & Dohme LLC | $15.56 | 2019 | |
| Nabriva Therapeutics, Plc | $13.67 | 2022 | |
| Epi Health, LLC | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Machnau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.